Skip Navigation
BDTX-4933

Oral, Brain-Penetrant MasterKey Inhibitor of Oncogenic BRAF Mutations

BDTX-4933 signaling


BDTX-4933 is a MasterKey inhibitor of Class I, II, and III oncogenic RAF mutations. Based on preclinical data, BDTX-4933 can also act as a “RAF-RAS clamp” that blocks mutant KRAS and NRAS signaling. Preclinical data demonstrating a potential best-in-class profile for BDTX-4933 were presented in 2023.

BDTX-4933 is currently in a Phase 1 trial for patients with KRAS mutant NSCLC. Learn more at clinicaltrials.gov.